Lunai Bioworks Inc. (NASDAQ:LNAI) Sees Large Decrease in Short Interest

Lunai Bioworks Inc. (NASDAQ:LNAI) was the recipient of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 345,109 shares, a decline of 86.1% from the May 14th total of 2,489,634 shares. Approximately 7.7% of the company’s shares are short sold. Based on an average daily volume of 217,022 shares, the days-to-cover ratio is currently 1.6 days.

Lunai Bioworks Price Performance

LNAI traded up $0.24 during trading on Thursday, reaching $2.50. The company had a trading volume of 40,253 shares, compared to its average volume of 131,099. Lunai Bioworks has a 12 month low of $1.21 and a 12 month high of $33.50. The business’s fifty day moving average price is $2.60 and its 200 day moving average price is $4.96. The company has a market cap of $11.33 million, a P/E ratio of -6.25 and a beta of 0.40.

Lunai Bioworks (NASDAQ:LNAI) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.80) earnings per share for the quarter. The business had revenue of $0.02 million for the quarter.

Analyst Ratings Changes

A number of research analysts recently issued reports on LNAI shares. Weiss Ratings restated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Friday, April 10th. Wall Street Zen upgraded shares of Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC purchased a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned approximately 0.87% of Lunai Bioworks at the end of the most recent quarter. 71.41% of the stock is currently owned by hedge funds and other institutional investors.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.